Skip header and navigation

Refine By

7 records – page 1 of 1.

Cost analysis of different phases of acute myeloid leukaemia.

https://arctichealth.org/en/permalink/ahliterature23516
Source
Leuk Res. 1994 Oct;18(10):783-90
Publication Type
Article
Date
Oct-1994
Author
A M Stalfelt
H. Brodin
B. Wadman
Author Affiliation
Department of Internal Medicine, Orebro Medical Center Hospital, Sweden.
Source
Leuk Res. 1994 Oct;18(10):783-90
Date
Oct-1994
Language
English
Publication Type
Article
Keywords
Acute Disease
Adult
Aged
Aged, 80 and over
Cost of Illness
Costs and Cost Analysis
Episode of Care
Female
Health Care Costs - statistics & numerical data
Humans
Leukemia, Myeloid - economics - mortality - therapy
Male
Middle Aged
Quality of Life
Recurrence
Remission Induction
Research Support, Non-U.S. Gov't
Sweden
Abstract
Priority lists have been formulated in several countries and cut-backs can be a threat to leukaemia treatment. We analysed the costs in different phases of disease for 54 conventionally treated patients with acute myeloid leukaemia. Thirty-two patients reached CR 1, seven patients are still alive as of May 1994. We found a cost per week and patient of 17,334 Swedish Crowns (SEK) (U.K. 1 pound = 10.57 and U.S. $1 = 5.91, 1990) in induction phase, 1854 in remission phase and 10,529 SEK in relapse phase. In the terminal phase 10% of the total cost was spent. The quality of life of the patients in relapse is discussed and palliative treatment is emphasized.
PubMed ID
7934137 View in PubMed
Less detail

[Individual oriented preventive medicine. 2. How? When? Where? Who pays?]

https://arctichealth.org/en/permalink/ahliterature74751
Source
Lakartidningen. 1971 Nov 24;68(48):5562-8
Publication Type
Article
Date
Nov-24-1971

Leukemia in workers exposed to ethylene oxide.

https://arctichealth.org/en/permalink/ahliterature27449
Source
JAMA. 1979 Mar 16;241(11):1132-3
Publication Type
Article
Date
Mar-16-1979
Author
C. Hogstedt
N. Malmqvist
B. Wadman
Source
JAMA. 1979 Mar 16;241(11):1132-3
Date
Mar-16-1979
Language
English
Publication Type
Article
Keywords
Adult
Disinfectants - adverse effects
Ethylene Oxide - adverse effects
Female
Humans
Leukemia - chemically induced
Leukemia, Myelocytic, Acute - chemically induced
Leukemia, Myeloid - chemically induced
Male
Middle Aged
Mutagens
Occupational Diseases - chemically induced
Sweden
Waldenstrom Macroglobulinemia - chemically induced
Abstract
Ethylene oxide, a gaseous sterilant extensively used within health care facilities, is known to be a mutagen in bacteria and in human lymphocytes. The Environmental Protection Agency as well as the National Institue of Occupational Safety and Health have recently stipulated certain conditions for the use of ethylene oxide despite the lack of case reports or epidemiologic studies concerning carcinogenicity. We report three cases of leukemia that occurred between 1972 and 1977 in a relatively small group of Swedish workers exposed to ethylene oxide. According to national statistics, 0.2 cases of leukemia would have been expected. The time-weighted average ethylene oxide concentration was 20+/-10 ppm.
PubMed ID
105157 View in PubMed
Less detail

Liver cirrhosis in three Scandinavian communities. An attempt at a critical evaluation of available epidemiologic data.

https://arctichealth.org/en/permalink/ahliterature13489
Source
Acta Med Scand. 1971 Mar;189(3):221-30
Publication Type
Article
Date
Mar-1971

Oxymetholone treatment in aregenerative anaemia. II. Remission and survival--a prospective study.

https://arctichealth.org/en/permalink/ahliterature27873
Source
Scand J Haematol. 1976 Feb;16(2):90-100
Publication Type
Article
Date
Feb-1976
Author
R. Hast
K O Skårberg
L. Engstedt
S. Jameson
A. Killander
B. Lundh
P. Reizenstein
A M Udén
B. Wadman
Source
Scand J Haematol. 1976 Feb;16(2):90-100
Date
Feb-1976
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Anemia, Aplastic - complications - drug therapy - mortality
Child
Female
Hepatitis, Toxic
Humans
Leukemia - etiology - mortality
Liver - drug effects
Male
Middle Aged
Oxymetholone - adverse effects - therapeutic use
Prognosis
Prospective Studies
Remission, Spontaneous
Sweden
Time Factors
Abstract
This is a prospective multi-center study in which patients with aregenerative anaemia were treated with a standardized high dosage regime of an anabolic steroid (oxymetholone, Anasteron). 53 patients were included and divided into two groups according to bone marrow cellularity. Furthermore the hypocellular group was subdivided in order to make comparison with earlier studies possible. In the hypocellular group, the frequency of remission was 56% and the 2-year-survival from the onset of symptoms was 75%. This is longer than in some earlier studies, perhaps because of possible differences in etiology and/or because of the effect of systematic high dosage, long term androgen therapy. Patient selection was minimized and was not considered to be of major importance. Patients with hypercellular marrows, on the other hand, responded poorly to androgens. In this group 63% died of acute leukaemia, which confirms earlier suggestions that this form of aregenerative anaemia, frequently is of a preleukaemic nature.
PubMed ID
1257703 View in PubMed
Less detail

[Suggestions from the National Board of Health and Welfare. Regional cooperation and new kinds of care are 2 of the key words in the cancer care of tomorrow]

https://arctichealth.org/en/permalink/ahliterature24834
Source
Lakartidningen. 1991 May 29;88(22):2079-80
Publication Type
Article
Date
May-29-1991

7 records – page 1 of 1.